Agios Pharmaceuticals (NASDAQ:AGIO) is up 5.8% postmarket after noting updated data from its ongoing perioperative study on vorasidenib or Tibsovo (ivosidenib) in low-grade glioma with an IDH1 mutation.
The data confirm brain penetrance and robust biomarker suppression, the company says.
The company’s on track to initiate its Phase 3 INDIGO study next month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.